Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma-- A Nationwide Multicentered Prospective Controlled Study

NCT05844813 is registered in ClinicalTrials.gov with Peking University International Hospital as lead sponsor.

NCT NCT05844813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05844813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma-- A Nationwide Multicentered Prospective Controlled Study
Lead sponsor
Peking University International Hospital
Phase
Phase 4
Overall status
Enrolling by invitation
Start date
November 1, 2022
Completion date
November 1, 2027
Enrollment
102 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

retroperitoneal sarcoma